Acknowledgments.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513.

2. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of coinfection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020;323:2085–2086.

3. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020;323:2249–2251.

4. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011;377:1264–1275.

5. Influenza surveillance: 2019–2020 flu activity report. Illinois Department of Public Health website. http://www.dph.illinois.gov/topics-services/diseases-and-conditions/influenza/influenza-surveillance. Published April 11, 2020. Accessed April 18, 2020.

SARS-CoV-2 screening of asymptomatic healthcare workers

Andrew P. Jameson MD, FACP1,2, Matthew P. Biersack MD, BS2, Tara M. Sebastian1 and Liberty R. Jacques DNP, RN, CIC2

1Michigan State University College of Human Medicine, Grand Rapids, Michigan and 2Mercy Health Saint Mary’s Hospital, Grand Rapids, Michigan

The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease (COVID-19) has evolved into a global pandemic that, as of June 9, 2020, has taken >400,000 lives worldwide and has halted public life.1

Many reports have now established that asymptomatic and presymptomatic individuals play an essential role in perpetuating the spread of disease.1–4 Transmission rates within the healthcare setting have varied in the literature.5–8 We developed this protocol to determine the SARS-CoV-2 positivity rate among asymptomatic HCWs at our institution.

To effectively cohort patients, we developed a broad plan for screening asymptomatic and presymptomatic admissions in a

Table 1. Positivity of Respiratory Panel Pathogens Stratified by SARS-CoV-2 Status

| Panel Pathogen                  | SARS-CoV-2 Positive, No. (%) (n = 459) | SARS-CoV-2 Negative, No. (%) (n = 2,076) | P Valuea |
|---------------------------------|---------------------------------------|----------------------------------------|----------|
| Respiratory panel               | 15 (3.3)                              | 349 (16.8)                             | <.001    |
| Adenovirus                      | 2 (0.4)                               | 25 (1.2)                               |          |
| Coronavirus 229E                | 0 (0.0)                               | 7 (0.3)                                |          |
| Coronavirus HKU1                | 0 (0.0)                               | 13 (0.5)                               |          |
| Coronavirus NL63                | 1 (0.2)                               | 51 (2.5)                               | .002     |
| Coronavirus OC43                | 0 (0.0)                               | 10 (0.5)                               |          |
| Human metapneumovirus           | 2 (0.4)                               | 48 (2.3)                               | .009     |
| Influenza A                     | 3 (0.7)                               | 49 (2.4)                               | .020     |
| Influenza B                     | 0 (0.0)                               | 13 (0.6)                               |          |
| Parainfluenza 1                 | 0 (0.0)                               | 1 (0.0)                                |          |
| Parainfluenza 2                 | 1 (0.2)                               | 0 (0.0)                                |          |
| Parainfluenza 3                 | 0 (0.0)                               | 1 (0.0)                                |          |
| Parainfluenza 4                 | 0 (0.0)                               | 3 (0.1)                                |          |
| Respiratory syncytial virus     | 0 (0.0)                               | 39 (1.9)                               | .003     |
| Mycoplasma pneumoniae           | 0 (0.0)                               | 0 (0.0)                                |          |
| Chlamydia pneumoniae            | 0 (0.0)                               | 3 (0.1)                                |          |
| Bordetella pertussis            | 0 (0.0)                               | 1 (0.0)                                |          |
| Rhinovirus/Enterovirus          | 8 (1.7)                               | 172 (8.3)                              | <.001    |

Note. SARS-CoV-2, severe acute respiratory syndrome coronavirus.

aStatistical significance determined by both χ2 and Fisher exact tests; χ2 P values listed.

Author for correspondence: Andrew P. Jameson, E-mail: andrew.jameson@mercyhealth.com

Cite this article: Jameson AP, et al. (2020). SARS-CoV-2 screening of asymptomatic healthcare workers. Infection Control & Hospital Epidemiology, 41: 1229–1231, https://doi.org/10.1017/ice.2020.361

© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
283-bed teaching hospital in an urban setting within Michigan. All inpatients admitted to the hospital were screened utilizing the GeneXpert RT-PCR platform (Cepheid, Sunnyvale, CA) via nasopharyngeal swabs. This screening program revealed that 1 in ~28 asymptomatic patients were positive for SARS-CoV-2. At the time of HCW testing, the community burden of SARS-CoV-2 remained high, with 515 active cases per 100,000 county residents.10 Within the hospital itself, there were, on average, 3.8 new COVID-19 admissions per day in the 2 weeks preceding and the 2 weeks during the employee testing window.

Methods
A voluntary SARS-CoV-2 testing program was offered to HCWs over a 2-week testing window. HCWs were excluded if they had symptoms of COVID-19 or previously tested positive for SARS-CoV-2. The program was made available to personnel who cared for COVID-19–positive patients in the ED or on the COVID-19 care unit. Screening was performed using nasopharyngeal swabs and the Cepheid GeneXpert RT-PCR assay. Staff were permitted to return to work while awaiting test results.

Results
In total, 499 staff members were eligible for screening. Among them, 121 personnel volunteered to undergo testing (24.2% of those eligible). The results of all 121 tests were negative for SARS-CoV-2. Breaking down the uptake in testing by role: 6 of 53 of eligible respiratory therapists (11.3%) were tested, 33 of 92 eligible providers (35.9%) were tested, 71 of 262 eligible registered nurses (27.1%) were tested, and 11 of 82 of the eligible patient care assistants (13.4%) were tested.

Discussion
The voluntary hospital staff testing program described here was implemented as a method of ensuring the safety of our personnel and patients from the established threat of asymptomatic transmission. Had any staff members received a positive test result, appropriate isolation measures would have been implemented to prevent viral spread, including a 10-day minimum administrative leave. The negative results of all tested individuals allowed these personnel to return to work in confidence and also informed the hospital’s decision to not continue routine testing of employees.

The 0% positive test rate among asymptomatic staff, despite the local community and hospital system experiencing a large burden of COVID-19 cases, is a testament to the ongoing work underway to ensure safety throughout the hospital. The following precautionary measures were implemented at our hospital:

- Universal SARS-CoV-2 testing of all patients admitted to the hospital, regardless of symptomatology or reason for stay
- Testing of all patients undergoing surgical procedures 24–48 hours prior to operation
- Isolation of all positive patients into designated COVID-19 care units
- Negative pressure ventilation systems for all COVID-19 care floors
- Personal protective equipment requirements including surgical masks and universal precautions on all floors, with the addition of gowns and eye protection on COVID-19 units
- Mandatory N95 mask or PAPR/CAPR use for any aerosol-generating procedures in COVID-19 units
- “No visitors” policy throughout the hospital, absent exigent circumstances (in accordance with Michigan’s March 14 executive order)
- Universal symptom screening of all staff arriving to work, excluding workers if they presented with any of the following symptoms: fever, cough, shortness of breath, chills, body aches, loss of taste, or loss of smell.

This testing was arranged through a COVID-specific Colleague Health Hotline designated to have a very low threshold for testing. Adherence to this protocol has been of utmost priority throughout the hospital, in part because the ramifications of nosocomial transmission became evident early in the pandemic. The hospital had numerous instances of SARS-CoV-2–positive patients admitted to non–COVID-19 units, with a significant delay in diagnosis due to atypical clinical presentations. This repeated exposure to SARS-CoV-2–positive patients on non–COVID-19 units informed the decision to proceed with this protocol.

The uptake in testing among potentially exposed healthcare workers was also measured. Moreover, the 24.2% of eligible healthcare workers pursuing testing was lower than we expected. It is unclear whether this represents reluctance to undergo a diagnostic nasopharyngeal swab or confidence in the organizational approach. Regardless, this relatively low uptake does not support routine testing as an effective method to improve workforce confidence or safety.

In the months since implementation, adherence to the listed protective measures has been central to the safety of the hospital community and has contributed to the lack of positive testing among asymptomatic HCWs. As statewide regulations and social distancing restrictions begin to relax, it is essential to adequately protect our healthcare workforce. The infection control methods described have demonstrated how this organization was able to effectively protect this vital resource. Extensive testing of employees does not seem to be cost-effective or necessary when strong symptom screening and infection control policies are in place. As hospitals and communities prepare for the next phase of the pandemic, we recommend close monitoring of employee symptoms, rapid access to testing when symptoms develop, strong infection control practices, and broad testing of patients to effectively cohort patients as an alternative to testing asymptomatic employees.

Acknowledgments. None.

Financial support. We thank the Saint Mary’s Foundation and Michelle Rabideau for funding this project.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References
1. Coronavirus disease (COVID-19) pandemic. World Health Organization website. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQjw--IjBRDkARlsAlcfmTEFNb4Xh JeffersonTeYPYyolufXu1BzXGJSHPAt8LPrzfnC-C.1aA0PEALw.wcB. Accessed June 11, 2020.
2. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406–1407.
3. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance 2020;25(10). doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
4. He X, Lau EH, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26:672–675.

https://doi.org/10.1017/ice.2020.361 Published online by Cambridge University Press
Universal screening for the SARS-CoV-2 virus on hospital admission in an area with low COVID-19 prevalence

Sangeeta R. Sastry MD, Rachel Pryor RN, MPH, Jillian E. Raybould MD, Julie Reznicek DO, Kaila Cooper RN, MSN, Amie Patrick RN, MSN, Shelley Knowlson RN, Pamela Bailey DO, MPH, Emily Godbout MD, MPH, Michelle Doll MD, MPH, Michael P. Stevens MD, MPH and Gonzalo Bearman MD, MPH
Division of Infectious Diseases, Virginia Commonwealth University, Richmond, Virginia

Asymptomatic persons contribute to widespread transmission of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic. Published reports from areas of high COVID-19 incidence in the United States suggest that a significant percentage of asymptomatic persons are in healthcare systems. In 2 New York City (NYC) hospitals, 13.7% of asymptomatic pregnant women admitted for delivery tested positive for SARS-CoV-2 virus. Similarly, the nursing facility in Washington state with the earliest death from COVID-19 infection and the first healthcare worker infected in the United States, reported >50% positivity of their asymptomatic residents for the virus. Universal screening of healthcare populations may prevent in-hospital transmission of SARS-CoV-2 virus. However, testing resources and personal protective equipment (PPE) supplies to effectively isolate positive asymptomatic persons are currently limited, resulting in provider safety concerns. Upon developing real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) tests in-house with >98% sensitivity, as well as increasing the availability of PPE at our institution, we initiated universal screening of patients on hospital admission using nasopharyngeal swabs to identify and isolate asymptomatic positive patients to prevent in-hospital transmission of SARS-CoV-2. We report our experience with universal screening of asymptomatic hospitalized persons, including a comparison of demographics between symptomatic and asymptomatic populations.

Methods
On April 27, 2020, our 1,000-bed academic center instituted universal SARS-CoV-2 testing of patients on hospital admission. Clinicians performed COVID-19 symptom screening using clinical criteria reported in the literature. They designated patients as symptomatic or asymptomatic when ordering the test. An infectious diseases physician conducted chart review of asymptomatic positive patients to confirm accuracy of classification. Asymptomatic patients were not isolated; test turnaround time was 6–24 hours.

Statistical analyses were performed with the Fischer exact tests and paired t tests to compare asymptomatic and symptomatic positive patients using SAS version 9.4 software (SAS Institute, Cary, NC).

Results
Between April 27, 2020, and May 18, 2020, when the hospital averaged at 60%–70% capacity, we performed 1,811 SARS-CoV-2 tests on nasopharyngeal specimens: 1,335 (74%) were asymptomatic, 420 (23%) were symptomatic, 56 (3%) were incorrectly ordered. Of the 1,755 tests in this analysis, overall positivity for SARS-CoV-2 virus was 79 (4.5%). Of 79 patients, 12 were asymptomatic (15%) and 67 were symptomatic (85%). Of 1,335 asymptomatic patients, 12 tested positive, for a rate of ~1%. Of 420 symptomatic patients, 67 tested positive, for a rate of 16%. No test converted to positive among asymptomatic patients while hospitalized.

A comparative analysis of patients with positive SARS-CoV-2 tests is listed in Table 1. The mean age of asymptomatic patients was 37 years (SD, 19.71) versus a mean age of 59 years (SD, 13.08) among symptomatic patients (P = .0020). Hispanic patients were more likely to be asymptomatic (7 of 12) than symptomatic (9 of 67) at the time of testing (58% vs 13%; P = .0017). We observed no difference in positivity rate on admission of asymptomatic versus symptomatic patients (P = .21). In addition, 5 asymptomatic positive women were pregnant (5 of 12, 42%); no symptomatic patients were pregnant (P ≤ .0001). A baby born to an asymptomatic SARS-CoV-2–positive mother tested positive at 48 hours of life, and 1 asymptomatic, SARS-CoV-2–positive, immunocompromised patient was receiving chemotherapy for breast cancer. One asymptomatic patient developed a fever during hospitalization, and another was readmitted within 14 days of testing positive, both of these events were not considered to be related to COVID-19.

5. Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 2020;395:1137–1144.
6. Canova V, Schlapfer H, Piso RJ, et al. Transmission risk of SARS-CoV-2 to healthcare workers—observational results of a primary care hospital contact tracing. Swiss Med Wkly 2020;150.
7. Ng K, Poon BH, Puar THK, et al. COVID-19 and the risk to health care workers: a case report. Ann Intern Med 2020;172:766–767.
8. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.
9. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177–1179.
10. COVID-19 data for Kent County, Michigan. accessKent website. https://www.accesskent.com/Health/covid-19-data.htm. Accessed June 11, 2020.

Author for correspondence: Sangeeta R. Sastry, E-mail: Sangeeta.Sastry@vcuhealth.org
Cite this article: Sastry SR, et al. (2020). Universal screening for the SARS-CoV-2 virus on hospital admission in an area with low COVID-19 prevalence. Infection Control & Hospital Epidemiology, 41: 1231–1233, https://doi.org/10.1017/ice.2020.358
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This is an Open Access article, distributed under the terms of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

https://doi.org/10.1017/ice.2020.361 Published online by Cambridge University Press